Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: Implications for therapeutics

Expert Reviews in Molecular Medicine

Volumn 12, Issue , 2010, Pages

  Albin, John S ^a   Harris, Reuben S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; COMPLEMENTARY DNA; CYTIDINE; UNCLASSIFIED DRUG; VIRION INFECTIVITY FACTOR; VIRUS DNA; VIRUS PROTEIN; VIRUS RNA; APOBEC3 PROTEIN, HUMAN; CYTOSINE DEAMINASE; VIF PROTEIN;

ADAPTATION; DEAMINATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION RISK; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN POLYMORPHISM; REVERSE TRANSCRIPTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; VIRAL GENE DELIVERY SYSTEM; VIRION; VIRUS GENE; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS LOAD; CHEMISTRY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PROTEIN BINDING; VIRUS CAPSID;

CAPSID; CYTOSINE DEAMINASE; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN BINDING; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77953035055     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1462399409001343     Document Type: Review

References (168)

1. Chiu, Y.L. and Greene, W.C. (2008) The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements. Annual Review of Immunology 26, 317-353
2. Harris, R.S. and Liddament, M.T. (2004) Retroviral restriction by APOBEC proteins. Nature Reviews Immunology 4, 868-877 (Pubitemid 39490762)
3. Malim, M.H. and Emerman, M. (2008) HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host and Microbe 3, 388-398 (Pubitemid 351784365)
4. Gramberg, T., Sunseri, N. and Landau, N.R. (2009) Accessories to the crime: recent advances in HIVaccessory protein biology. Current HIV/AIDS Reports 6, 36-42
5. Garrett, E.D., Tiley, L.S. and Cullen, B.R. (1991) Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. Journal of Virology 65, 1653-1657
6. Schwartz, S., Felber, B.K. and Pavlakis, G.N. (1991) Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology 183, 677-686
7. Kan, N.C. et al. (1986) Identification of HTLV-III/ LAV sor gene product and detection of antibodies in human sera. Science 231, 1553-1555 (Pubitemid 16050723)
8. Lee, T.H. et al. (1986)A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science 231, 1546-1549
9. Sodroski, J. et al. (1986) Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science 231, 1549-1553 (Pubitemid 16050722)
10. Desrosiers, R.C. et al. (1998) Identification of highly attenuated mutants of simian immunodeficiency virus. Journal of Virology 72, 1431-1437 (Pubitemid 28116930)
11. Strebel, K. et al. (1987) The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328, 728-730 (Pubitemid 17125778)
12. Gabuzda, D.H. et al. (1992) Role of Vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. Journal of Virology 66, 6489-6495
13. Gabuzda, D.H. et al. (1994) Essential role of vif in establishing productive HIV-1 infection in peripheral blood T lymphocytes and monocyte/ macrophages. Journal of Acquired Immune Deficiency Syndromes 7, 908-915
14. Fisher, A.G. et al. (1987) The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 237, 888-893 (Pubitemid 17128277)
15. Simon, J.H. and Malim, M.H. (1996) The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. Journal of Virology 70, 5297-5305 (Pubitemid 26240703)
16. Courcoul, M. et al. (1995) Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. Journal of Virology 69, 2068-2074
17. Goncalves, J. et al. (1996) Role of Vif in human immunodeficiency virus type 1 reverse transcription. Journal of Virology 70, 8701-8709 (Pubitemid 26378452)
18. Sova, P. and Volsky, D.J. (1993) Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with vif-negative human immunodeficiency virus type 1. Journal of Virology 67, 6322-6326 (Pubitemid 23277551)
19. Madani, N. and Kabat, D. (1998) An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. Journal of Virology 72, 10251-10255 (Pubitemid 28520900)
20. Simon, J.H. et al. (1998) Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nature Medicine 4, 1397-1400 (Pubitemid 28553462)
21. Sheehy, A.M. et al. (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650
22. Haché, G. et al. (2008) Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Current Biology 18, 819-824
23. Jarmuz, A. et al. (2002) An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296 (Pubitemid 34211936)
24. Petersen-Mahrt, S.K., Harris, R.S. and Neuberger, M.S. (2002) AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418, 99-103 (Pubitemid 34742579)
25. Harris, R.S., Petersen-Mahrt, S.K. and Neuberger, M.S. (2002) RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Molecular Cell 10, 1247-1253 (Pubitemid 35453840)
26. Harris, R.S. et al. (2003) DNA deamination mediates innate immunity to retroviral infection. Cell 113, 803-809 (Pubitemid 36724943)
27. Mangeat, B. et al. (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99-103 (Pubitemid 36834849)
28. Zhang, H. et al. (2003) The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424, 94-98 (Pubitemid 36834848)
29. Lecossier, D. et al. (2003) Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300, 1112 (Pubitemid 36583087)
30. Browne, E.P., Allers, C. and Landau, N.R. (2009) Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 387, 313-321
31. Holmes, R.K. et al. (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. Journal of Biological Chemistry 282, 2587-2595 (Pubitemid 47076764)
32. Miyagi, E. et al. (2007) Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. Journal of Virology 81, 13346-13353 (Pubitemid 350247831)
33. Schumacher, A.J. et al. (2008) The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. Journal of Virology 82, 2652-2660 (Pubitemid 351329156)
34. Shindo, K. et al. (2003) The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. Journal of Biological Chemistry 278, 44412-44416 (Pubitemid 37377191)
35. Newman, E.N. et al. (2005) Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Current Biology 15, 166-170
36. Bishop, K.N., Holmes, R.K. and Malim, M.H. (2006) Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. Journal of Virology 80, 8450-8458 (Pubitemid 44384857)
37. Bishop, K.N. et al. (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathogens 4, e1000231
38. Iwatani, Y. et al. (2007) Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Research 35, 7096-7108
39. Guo, F. et al. (2006) Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. Journal of Virology 80, 11710-11722 (Pubitemid 44788884)
40. Yang, Y. et al. (2007) Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 365, 92-100 (Pubitemid 46907232)
41. Li, X.Y. et al. (2007) APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. Journal of Biological Chemistry 282, 32065-32074
42. Luo, K. et al. (2007) Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. Journal of Virology 81, 7238-7248 (Pubitemid 46986660)
43. Mbisa, J.L. et al. (2007) HIV-1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. Journal of Virology 81, 7099-7110 (Pubitemid 46986646)
44. Schumacher, A.J., Nissley, D.V. and Harris, R.S. (2005) APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proceedings of the National Academy of Sciences of the United States of America 102, 9854-9859 (Pubitemid 40993657)
45. Turelli, P. et al. (2004) Inhibition of hepatitis B virus replication by APOBEC3G. Science 303, 1829 (Pubitemid 38374868)
46. Bogerd, H.P. et al. (2006) Cellular inhibitors of long interspersed element 1 and Alu retrotransposition. Proceedings of the National Academy of Sciences of the United States of America 103, 8780-8785 (Pubitemid 43878096)
47. Muckenfuss, H. et al. (2006) APOBEC3 proteins inhibit human LINE-1 retrotransposition. Journal of Biological Chemistry 281, 22161-22172 (Pubitemid 44181920)
48. Stenglein, M.D. and Harris, R.S. (2006) APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. Journal of Biological Chemistry 281, 16837-16841
49. Holmes, R.K., Malim, M.H. and Bishop, K.N. (2007) APOBEC-mediated viral restriction: not simply editing? Trends in Biochemical Sciences 32, 118-128 (Pubitemid 46367691)
50. Bonvin, M. and Greeve, J. (2008) Hepatitis B: modern concepts in pathogenesis - APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus. Current Opinion in Infectious Diseases 21, 298-303 (Pubitemid 351620385)
51. Harris, R.S. et al. (2003)DNAdeamination: not just a trigger for antibody diversification but also a mechanism for defense against retroviruses. Nature Immunology 4, 641-643 (Pubitemid 36874436)
52. Yang, B. et al. (2007) Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA. Journal of Biological Chemistry 282, 11667-11675 (Pubitemid 47100658)
53. Chen, R. et al. (2004) Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. Journal of Biological Chemistry 279, 28419-28425 (Pubitemid 38900122)
54. Mansky, L.M. et al. (2000) The interaction of vpr with uracil DNA glycosylase modulates the human immunodeficiency virus type 1 In vivo mutation rate. Journal of Virology 74, 7039-7047 (Pubitemid 30470687)
55. Priet, S. et al. (2005) HIV-1-associated uracil DNA glycosylase activity controls dUTP misincorporation in viral DNA and is essential to the HIV-1 life cycle. Molecular Cell 17, 479-490 (Pubitemid 40269113)
56. Schröfelbauer, B. et al. (2005) Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases. Journal of Virology 79, 10978-10987 (Pubitemid 41170639)
57. Kaiser, S.M. and Emerman, M. (2006) Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase APOBEC3G. Journal of Virology 80, 875-882 (Pubitemid 43062899)
58. Conticello, S.G., Harris, R.S. and Neuberger, M.S. (2003) The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Current Biology 13, 2009-2013 (Pubitemid 37425213)
59. Marin, M. et al. (2003) HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Medicine 9, 1398-1403 (Pubitemid 37466189)
60. Sheehy, A.M., Gaddis, N.C. and Malim, M.H. (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Medicine 9, 1404-1407 (Pubitemid 37466190)
61. Stopak, K. et al. (2003)HIV-1Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Molecular Cell 12, 591-601 (Pubitemid 37222482)
62. Yu, X. et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif- Cul5-SCF complex. Science 302, 1056-1060 (Pubitemid 37386201)
63. Mehle, A. et al. (2004) Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. Journal of Biological Chemistry 279, 7792-7798 (Pubitemid 38294663)
64. Mehle, A. et al. (2004) Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif- Cul5 complex that promotes APOBEC3G degradation. Genes and Development 18, 2861-2866 (Pubitemid 39602304)
65. Yu, Y. et al. (2004) Selective assembly of HIV-1 Vif- Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes and Development 18, 2867-2872 (Pubitemid 39602305)
66. Kao, S. et al. (2003) The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. Journal of Virology 77, 11398-11407 (Pubitemid 37271638)
67. Mariani, R. et al. (2003) Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114, 21-31 (Pubitemid 36859838)
68. Santa-Marta, M. et al. (2005) HIV-1 Vif can directly inhibit apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. Journal of Biological Chemistry 280, 8765-8775 (Pubitemid 40409564)
69. Conticello, S.G. et al. (2005) Evolution of the AID/ APOBEC family of polynucleotide (deoxy)cytidine deaminases. Molecular Biology and Evolution 22, 367-377 (Pubitemid 40130201)
70. Wedekind, J.E. et al. (2003) Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends in Genetics 19, 207-216 (Pubitemid 36398423)
71. Malim, M.H. (2009) APOBEC proteins and intrinsic resistance to HIV-1 infection. Philosophical Transactions of the Royal Society of London Series B Biological Sciences 364, 675-687
72. Li, Q. et al. (2009) Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection. Journal of Immunology 183, 1975-1982
73. Oh Ainle, M. et al. (2008) Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host and Microbe 4, 249-259
74. Harari, A. et al. (2009) Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. Journal of Virology 83, 295-303
75. Tan, L. et al. (2009) Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB Journal 23, 279-287
76. Yu, Q. et al. (2004) APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. Journal of Biological Chemistry 279, 53379-53386 (Pubitemid 40051843)
77. Yu, Q. et al. (2004) Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nature Structural and Molecular Biology 11, 435-442 (Pubitemid 38568947)
78. Bishop, K.N. et al. (2004) Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Current Biology 14, 1392-1396 (Pubitemid 39081643)
79. Liddament, M.T. et al. (2004) APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Current Biology 14, 1385-1391 (Pubitemid 39081642)
80. Wiegand, H.L. et al. (2004) A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO Journal 23, 2451-2458 (Pubitemid 38954852)
81. Zheng, Y.H. et al. (2004) Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. Journal of Virology 78, 6073-6076
82. Watts, J.M. et al. (2009) Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 460, 711-716
83. Janini, M. et al. (2001) Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) Tcells. Journal of Virology 75, 7973-7986
84. Vartanian, J.P. et al. (1991) Selection, recombination, and G - A hypermutation of human immunodeficiency virus type 1 genomes. Journal of Virology 65, 1779-1788
85. Vartanian, J.P. et al. (1994) G- >. A hypermutation of the human immunodeficiency virus type 1 genome: evidence fordCTP pool imbalance during reverse transcription. Proceedings of the National Academy of Sciences of the United States of America 91, 3092-3096 (Pubitemid 2073862)
86. Pathak, V.K. and Temin, H.M. (1990) Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proceedings of the National Academy of Sciences of the United States of America 87, 6019-6023
87. Kieffer, T.L. et al. (2005) G - >. A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ Tcells in vivo. Journal of Virology 79, 1975-1980 (Pubitemid 40459148)
88. Pace, C. et al. (2006) Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation. Journal of Virology 80, 9259-9269 (Pubitemid 44359998)
89. Piantadosi, A. et al. (2009) Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective Vif. Journal of Virology 83, 7805-7814
90. Land, A.M. et al. (2008)Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. Journal of Virology 82, 8172-8182
91. Gandhi, S.K. et al. (2008) Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors. Journal of Virology 82, 3125-3130 (Pubitemid 351329200)
92. Ulenga, N.K. et al. (2008) The level of APOBEC3G (hA3G)-related G-to-A mutations does not correlate with viral load in HIV type 1-infected individuals. AIDS Research and Human Retroviruses 24, 1285-1290
93. Kidd, J.M. et al. (2007) Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genetics 3, e63
94. Mulder, L.C., Harari, A. and Simon, V. (2008) Cytidine deamination induced HIV-1 drug resistance. Proceedings of the National Academy of Sciences of the United States of America 105, 5501-5506 (Pubitemid 351753892)
95. Berkhout, B. and de Ronde, A. (2004) APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 18, 1861-1863 (Pubitemid 39179645)
96. Haché, G., Mansky, L.M. and Harris, R.S. (2006) Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance. AIDS Reviews 8, 148-157 (Pubitemid 44614032)
97. Pillai, S.K., Wong, J.K. and Barbour, J.D. (2008) Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 5, 26
98. Jern, P. et al. (2009) Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathogens 5, e1000367
99. Wood, N. et al. (2009) HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathogens 5, e1000414
100. Vázquez-Pérez, J.A. et al. (2009) APOBEC3G mRNA expression in exposed seronegative and early stage HIV infected individuals decreases with removal of exposure and with disease progression. Retrovirology 6, 23
101. Jin, X. et al. (2005) APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia. Journal of Virology 79, 11513-11516 (Pubitemid 41170693)
102. Cho, S.J. et al. (2006) APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count. Journal of Virology 80, 2069-2072
103. Ulenga, N.K. et al. (2008) Relationship between human immunodeficiency type 1 infection and expression of human APOBEC3G and APOBEC3F. Journal of Infectious Diseases 198, 486-492
104. Biasin, M. et al. (2007) Apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G: a possible role in the resistance to HIV of HIVexposed seronegative individuals. Journal of Infectious Diseases 195, 960-964 (Pubitemid 46452100)
105. Do, H. et al. (2005) Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. Journal of Infectious Diseases 191, 159-163 (Pubitemid 40096372)
106. An, P. et al. (2004) APOBEC3G genetic variants and their influence on the progression to AIDS. Journal of Virology 78, 11070-11076 (Pubitemid 39299647)
107. Valcke, H.S. et al. (2006) APOBEC3G genetic variants and their association with risk of HIV infection in highly exposed Caucasians. AIDS 20, 1984-1986 (Pubitemid 44427620)
108. An, P. et al. (2009) APOBEC3B deletion and risk of HIV-1 acquisition. Journal of Infectious Diseases 200, 1054-1058
109. OhAinle, M. et al. (2006) Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H. Journal of Virology 80, 3853-3862
110. Sawyer, S.L., Emerman, M. and Malik, H.S. (2004) Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biology 2, E275
111. Chiu, Y.L. et al. (2005)Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 435, 108-114
112. Chen, K. et al. (2006) Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. Journal of Virology 80, 7645-7657 (Pubitemid 44092585)
113. Santoni de Sio, F.R. and Trono, D. (2009) APOBEC3G-depleted resting CD4+ T cells remain refractory to HIV1 infection. PLoS One 4, e6571
114. Kamata, M., Nagaoka, Y. and Chen, I.S. (2009) Reassessing the role of APOBEC3G in human immunodeficiency virus type 1 infection of quiescent CD4+ T-cells. PLoS Pathogens 5, e1000342
115. Vetter, M.L. et al. (2009) Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity. PLoS Pathogens 5, e1000292
116. Koning, F.A. et al. (2009) Defining APOBEC3 Expression Patterns in Human Tissues and Hematopoietic Cell Subsets. Journal of Virology 83, 9474-9485
117. Peng, G. et al. (2007) Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 110, 393-400 (Pubitemid 47026861)
118. Pion, M. et al. (2006) APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. Journal of Experimental Medicine 203, 2887-2893 (Pubitemid 46026166)
119. Peng, G. et al. (2006) Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. Journal of Experimental Medicine 203, 41-46
120. Russell, R.A. and Pathak, V.K. (2007) Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. Journal of Virology 81, 8201-8210 (Pubitemid 47101506)
121. Simon, V. et al. (2005) Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathogens 1, e6
122. Zhang, W. et al. (2008) Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host antiviral proteins. PLoS One 3, e3963
123. He, Z. et al. (2008) Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. Journal of Molecular Biology 381, 1000-1011
124. Tian, C. et al. (2006) Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. Journal of Virology 80, 3112-3115 (Pubitemid 43346410)
125. Yamashita, T. et al. (2008) Identification of amino acid residues in HIV-1 Vif critical for binding and exclusion of APOBEC3G/F. Microbes and Infection 10, 1142-1149
126. Huthoff, H. et al. (2009) RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathogens 5, e1000330
127. Huthoff, H. and Malim, M.H. (2007) Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. Journal of Virology 81, 3807-3815 (Pubitemid 46586878)
128. Russell, R.A. et al. (2009) Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif. Journal of Virology 83, 1992-2003
129. Zhang, L. et al. (2008) Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology 370, 113-121 (Pubitemid 350179917)
130. Pery, E. et al. (2009) Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. Journal of Virology 83, 2374-2381
131. Chen, G. et al. (2009) A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. Journal of Virology 83, 8674-8682
132. Dang, Y. et al. (2009) Identification of a novel WxSLVK motif in the N terminus of human immunodeficiency virus and simian immunodeficiency virus Vif that is critical for APOBEC3G and APOBEC3F neutralization. Journal of Virology 83, 8544-8552
133. Harjes, E. et al. (2009) An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. Journal of Molecular Biology 389, 819-832
134. Nathans, R. et al. (2008) Small-molecule inhibition of HIV-1 Vif. Nature Biotechnology 26, 1187-1192
135. Chen, K.M. et al. (2008) Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452, 116-119
136. Holden, L.G. et al. (2008) Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456, 121-124
137. Furukawa, A. et al. (2009) Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBO Journal 28, 440-451
138. Prochnow, C. et al. (2007) The APOBEC-2 crystal structure and functional implications for the deaminase AID. Nature 445, 447-451 (Pubitemid 46160914)
139. Bransteitter, R., Prochnow, C. and Chen, X.S. (2009) The current structural and functional understanding of APOBEC deaminases. Cellular and Molecular Life Sciences 66, 3137-3147
140. Mitsuyasu, R.T. et al. (2009) Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nature Medicine 15, 285-292
141. Hutter, G. et al. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. New England Journal of Medicine 360, 692-698
142. Rossi, J.J., June, C.H. and Kohn, D.B. (2007) Genetic therapies against HIV. Nature Biotechnology 25, 1444-1454 (Pubitemid 350233141)
143. Bogerd, H.P. et al. (2004) A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proceedings of the National Academy of Sciences of the United States of America 101, 3770-3774 (Pubitemid 38381053)
144. Mangeat, B. et al. (2004) A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. Journal of Biological Chemistry 279, 14481-14483 (Pubitemid 38618833)
145. Schröfelbauer, B., Chen, D. and Landau, N.R. (2004) A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proceedings of the National Academy of Sciences of the United States of America 101, 3927-3932 (Pubitemid 38381079)
146. Xu, H. et al. (2004)Asingle amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proceedings of the National Academy of Sciences of the United States of America 101, 5652-5657 (Pubitemid 38481211)
147. Li, L. et al. (2008) APOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replication. Retrovirology 5, 72
148. Yamanaka, S. et al. (1995) Apolipoprotein B mRNA-editing protein induces hepatocellular carcinoma and dysplasia in transgenic animals. Proceedings of the National Academy of Sciences of the United States of America 92, 8483-8487
149. Ao, Z. et al. (2008) Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection. PLoS One 3, e1995
150. Aguiar, R.S. et al. (2008) Vpr.A3A chimera inhibits HIV replication. Journal of Biological Chemistry 283, 2518-2525
151. Green, L.A., Liu, Y. and He, J.J. (2009) Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy. Journal of Biological Chemistry 284, 13363-13372
152. Goila-Gaur, R. et al. (2007) Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 4, 61
153. Marin, M. et al. (2008) Human immunodeficiency virus type 1 Vif functionally interacts with diverse APOBEC3 cytidine deaminases and moves with them between cytoplasmic sites of mRNA metabolism. Journal of Virology 82, 987-998
154. Rose, K.M. et al. (2005) Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G. AIDS Research and Human Retroviruses 21, 611-619 (Pubitemid 41113649)
155. Bogerd, H.P. et al. (2008) Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. Journal of Virology 82, 11889-11901
156. Bogerd, H.P. et al. (2006) APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells. Nucleic Acids Research 34, 89-95 (Pubitemid 43167918)
157. Chen, H. et al. (2006) APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons. Current Biology 16, 480-485 (Pubitemid 43343708)
158. Gooch, B.D. and Cullen, B.R. (2008) Functional domain organization of human APOBEC3G. Virology 379, 118-124
159. Kinomoto, M. et al. (2007) All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition. Nucleic Acids Research 35, 2955-2964 (Pubitemid 47073634)
160. Bogerd, H.P. et al. (2007) The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 364, 486-493 (Pubitemid 46873711)
161. Doehle, B.P., Schafer, A. and Cullen, B.R. (2005) Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. Virology 339, 281-288 (Pubitemid 41169795)
162. Hakata, Y. and Landau, N.R. (2006) Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains. Journal of Biological Chemistry 281, 36624-36631 (Pubitemid 46042129)
163. Langlois, M.A. et al. (2005) Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into theirDNAtarget site specificities. Nucleic Acids Research 33, 1913-1923
164. Dang, Y. et al. (2008) Human cytidine deaminase APOBEC3H restricts HIV-1 replication. Journal of Biological Chemistry 283, 11606-11614
165. Dang, Y. et al. (2006) Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family. Journal of Virology80, 10522-10533 (Pubitemid 44628899)
166. Han, Y. et al. (2008) APOBEC3G and APOBEC3F require an endogenous cofactor to block HIV-1 replication. PLoS Pathogens 4, e1000095
167. Li, M.M., Wu, L.I. and Emerman, M. (2010) The range of human APOBEC3H sensitivity to lentiviral Vif proteins. Journal of Virology 84, 88-95
168. Stenglein, M.D. et al. (2010) APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nature Structural & Molecular Biology Jan 10; [Epub ahead of print]